1. Volume 359, Issue 9323, Pages 2065-2071 (June 2002)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial 
Prof Norbert Schmitz, MD, Beate Pfistner, PhD, Michael Sextro, MD, Markus Sieber, MD, Prof Angelo M Carella, MD, Matthias Haenel, MD, Friederike Boissevain, MD, Prof Reinhart Zschaber, MD, Peter Müller, MD, Hartmut Kirchner, MD, Andreas Lohri, MD, Susanne Decker, MD, Bettina Koch, Dirk Hasenclever, PhD, Anthony H Goldstone, FRCPath, Prof Volker Diehl, MD 
The Lancet 
Volume 359, Issue 9323, Pages (June 2002)
DOI: /S (02)
Copyright © 2002 Elsevier Ltd Terms and Conditions

2. Figure 1
Study protocol
Dexa-BEAM=dexamethasone and carmustine, etoposide, cytarabine, and melphalan; CR=complete remission; PR=partial remission; HSC=autologous haemopoietic stem cells; BM=bone marrow; HSCT=haemopoietic stem-cell transplantation.
The Lancet  , DOI: ( /S (02) )
Copyright © 2002 Elsevier Ltd Terms and Conditions

3. Figure 2 Trial profile CR=complete remission; PR=partial remission.
The Lancet  , DOI: ( /S (02) )
Copyright © 2002 Elsevier Ltd Terms and Conditions

4. Figure 3
Freedom from treatment failure for patients with relapsed chemosensitive Hodgkin's disease
The Lancet  , DOI: ( /S (02) )
Copyright © 2002 Elsevier Ltd Terms and Conditions

5. Figure 4
Freedom from treatment failure for patients with early relapse (upper), late relapse (middle), and multiple relapses (lower) of Hodgkin's disease
The Lancet  , DOI: ( /S (02) )
Copyright © 2002 Elsevier Ltd Terms and Conditions

6. Figure 5
Overall survival for patients with early relapse (upper), late relapse (middle), and multiple relapses (lower) of Hodgkin's disease.
The Lancet  , DOI: ( /S (02) )
Copyright © 2002 Elsevier Ltd Terms and Conditions